CCN1 and prostate carcinoma: An increasing number of studies have proved CYR61 to be a metastatic biomarker for prediction of prognosis in osteosarcoma [21], gastric cancer [22], colorectal cancer [16], laryngeal tumor [35], ovarian carcinoma [36] and prostate cancer [37].